Corbus Pharmaceuticals (CRBP) – Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Corbus Pharmaceuticals (NASDAQ: CRBP):

• 10/29/2025 – Corbus Pharmaceuticals was given a new $39.00 price target on by analysts at Mizuho.
• 10/20/2025 – Corbus Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $51.00 price target on the stock.
• 10/20/2025 – Corbus Pharmaceuticals had its “reduce” rating reaffirmed by analysts at Benchmark Co..
• 10/20/2025 – Corbus Pharmaceuticals had its price target raised by analysts at Wedbush from $31.00 to $38.00. They now have an “outperform” rating on the stock.
• 10/20/2025 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 10/8/2025 – Corbus Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Corbus Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/17/2025 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.

Insider Activity at Corbus Pharmaceuticals

In other news, CEO Yuval Cohen sold 18,660 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $17.01, for a total transaction of $317,406.60. Following the transaction, the chief executive officer directly owned 138,187 shares of the company’s stock, valued at approximately $2,350,560.87. This trade represents a 11.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean F. Moran sold 12,981 shares of the stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $17.02, for a total transaction of $220,936.62. Following the sale, the chief financial officer owned 73,313 shares in the company, valued at $1,247,787.26. This represents a 15.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 41,674 shares of company stock worth $713,870 over the last ninety days. Insiders own 3.60% of the company’s stock.

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.